(Q34826546)

4 August 2017

1 reference

title

Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis (English)

1 reference

4 August 2017

1 reference

1 reference

Mark Harries

1

1 reference

PubMed ID

12217790

4 August 2017

Martin Gore

series ordinal

2

1 reference

4 August 2017

1 September 2002

1 reference

Lancet Oncology Commission

4 August 2017

1 reference

4 August 2017

3

1 reference

4 August 2017

529-536

1 reference

4 August 2017

9

1 reference

4 August 2017

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

DNA index reflects the biological behavior of ovarian carcinoma stage I-IIa

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Management of ovarian cancer: referral to a multidisciplinary team matters

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

High dose cisplatin and high dose carboplatin in refractory ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900846-X

7 January 2021

10.1016/S1470-2045(02)00846-X

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12217790